CN107496438B - Application of Phellinus linteus polysaccharide in preparing medicine and health food - Google Patents
Application of Phellinus linteus polysaccharide in preparing medicine and health food Download PDFInfo
- Publication number
- CN107496438B CN107496438B CN201710974040.XA CN201710974040A CN107496438B CN 107496438 B CN107496438 B CN 107496438B CN 201710974040 A CN201710974040 A CN 201710974040A CN 107496438 B CN107496438 B CN 107496438B
- Authority
- CN
- China
- Prior art keywords
- intestinal
- phellinus linteus
- polysaccharide
- linteus polysaccharide
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000001727 Tropicoporus linteus Species 0.000 title claims abstract description 45
- 150000004676 glycans Chemical class 0.000 title claims abstract description 44
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 44
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 235000013402 health food Nutrition 0.000 title claims abstract description 17
- 230000000968 intestinal effect Effects 0.000 claims abstract description 65
- 208000036649 Dysbacteriosis Diseases 0.000 claims abstract description 11
- 208000027244 Dysbiosis Diseases 0.000 claims abstract description 11
- 230000007140 dysbiosis Effects 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 241000605894 Porphyromonas Species 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 208000008589 Obesity Diseases 0.000 abstract description 7
- 235000020824 obesity Nutrition 0.000 abstract description 7
- 208000011231 Crohn disease Diseases 0.000 abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- 230000004888 barrier function Effects 0.000 abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 5
- 230000008859 change Effects 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 5
- 235000009200 high fat diet Nutrition 0.000 abstract description 5
- 208000012868 Overgrowth Diseases 0.000 abstract description 4
- 235000021070 high sugar diet Nutrition 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 26
- 239000002158 endotoxin Substances 0.000 description 17
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 9
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000004232 Enteritis Diseases 0.000 description 5
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 5
- 101150030755 Ocln gene Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000123107 Phellinus Species 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101001086785 Homo sapiens Occludin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102100032604 Occludin Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Phellinus linteus polysaccharide in the fields of preparing medicines and health foods, and the product has the functions of regulating intestinal flora, inhibiting overgrowth of harmful bacteria caused by high-sugar and high-fat diet and recovering intestinal immune barrier effect. Can be used for treating or preventing intestinal dysbacteriosis, obesity, nonalcoholic fatty liver disease, diabetes, hyperlipidemia, cardiovascular and cerebrovascular diseases, crohn's disease, enteritis, and depression caused by intestinal flora structural change.
Description
Technical Field
The invention relates to the technical field of pharmacy and health-care food, in particular to application of Phellinus linteus polysaccharide in preparation of medicines and health-care food.
Background
The intestinal tract of human body has a large quantity of bacteria, namely intestinal flora, about 100 kinds of bacteria, the number of strains is more than 400, the total weight is about 1.5 kg, and the total number of bacteria is more than 10 times of the number of cells of an adult individual. The intestinal flora has important influence on normal physiological functions and health of human bodies, can synthesize various vitamins and short-chain fatty acids which are necessary for the human bodies, participate in metabolism of saccharides, lipids and proteins, promote absorption of mineral elements such as iron, magnesium, zinc and the like, have the effect of regulating immunity, resist infection and disease risks of autoimmune diseases, and even can influence and regulate nerve functions. The intestinal tract is not only an important digestive organ, but also a largest immune organ of a human body due to the action of intestinal flora, and is known as a second brain. A great deal of researches at present find that the composition proportion and the number of intestinal flora have important influence on the metabolism of sugar and the insulin sensitivity, the insulin sensitivity can be enhanced by adjusting the composition of the intestinal flora, the insulin resistance and the high insulin level of type II diabetics can be improved, and metabolic diseases such as obesity, non-alcoholic fatty liver, diabetes, hyperlipidemia and the like can be prevented and treated.
Phellinus linteus (Phellinus linteus), which is mostly parasitized on the dried stumps of broad-leaved trees such as mulberry, is a traditional fungus traditional Chinese medicine, and Phellinus Linteus Polysaccharide (PLP) is a main medicinal active ingredient, and researches show that the Phellinus linteus polysaccharide has the effects of resisting cancer, preventing cancer, relieving pain, regulating human immunity, preventing and treating liver cirrhosis, liver ascites and the like, but has no public report on the treatment or prevention effect of intestinal flora imbalance.
Disclosure of Invention
The invention mainly aims at providing application of Phellinus linteus polysaccharide in preparing medicines and health foods, and aims at providing new application of Phellinus linteus polysaccharide.
In order to achieve the aim, the invention provides application of Phellinus linteus polysaccharide in preparing medicines for treating or preventing intestinal dysbacteriosis.
The invention also provides application of Phellinus linteus polysaccharide in preparing medicines and health foods for inhibiting growth of intestinal porphyromonas.
The invention also provides application of Phellinus linteus polysaccharide in preparing medicines and health foods for treating obesity caused by intestinal dysbacteriosis.
The invention also provides application of the Phellinus linteus polysaccharide in preparing medicines and health foods for nonalcoholic fatty liver caused by intestinal dysbacteriosis.
The invention also provides application of the Phellinus linteus polysaccharide in preparing medicines and health foods for treating diabetes caused by intestinal dysbacteriosis.
The invention also provides application of the Phellinus linteus polysaccharide in preparing medicines and health foods for treating hyperlipidemia caused by intestinal dysbacteriosis.
The invention also provides application of the Phellinus linteus polysaccharide in preparing medicines and health foods for treating cardiovascular and cerebrovascular diseases caused by intestinal dysbacteriosis.
The invention also provides application of Phellinus linteus polysaccharide in preparing medicines and health foods for treating Crohn's disease caused by intestinal dysbacteriosis.
The invention also provides application of Phellinus linteus polysaccharide in preparing medicine and health food for treating enteritis caused by intestinal dysbacteriosis.
The invention also provides application of the Phellinus linteus polysaccharide in preparing medicines and health foods for treating depression caused by dysbacteriosis of intestinal tracts.
The new application of Phellinus linteus polysaccharide in pharmacy can inhibit overgrowth of harmful bacteria caused by high-sugar and high-fat diet by regulating intestinal flora composition and restore intestinal immune barrier effect, so that the Phellinus linteus polysaccharide can be used for treating or preventing intestinal flora imbalance, and can also be used for treating or preventing obesity, non-alcoholic fatty liver, diabetes, hyperlipidemia, cardiovascular and cerebrovascular diseases, crohn's disease, enteritis, depression and other diseases caused by intestinal flora structural change.
Drawings
The technical effects of the Phellinus linteus polysaccharide in preparing medicines and health foods provided by the invention are further described with reference to the accompanying drawings.
FIG. 1 is a PCR-DGGE analysis map of intestinal flora composition of each group of experimental mice;
FIG. 2 is a graph showing comparison of the expression level of OCLN mRNA in each group of experimental mice;
FIG. 3 is a graph showing comparison of TJPL mRNA expression levels in each group of experimental mice;
FIG. 4 is a graph showing comparison of serum endotoxin LPS levels of each group of experimental mice.
Detailed Description
The following experiments for using Phellinus linteus polysaccharide to interfere with high sugar and high lipid diet induced obesity mice are combined to illustrate the effect of Phellinus linteus polysaccharide in pharmacy.
60 male C57BL/6 mice are taken as experimental subjects and are divided into three groups, 20 mice are fed to each group, and the feeding method of each group is as follows:
group a (standard feed group): feeding with standard feed for 16 weeks, wherein the mice are subjected to physiological saline gastric lavage treatment twice a day at a physiological saline gastric lavage dose of 10mL/kg body weight in the latter 4 weeks;
group b (high sugar high fat feed group): feeding with high-sugar and high-fat feed for 16 weeks, wherein the mice are subjected to physiological saline gastric lavage treatment twice a day in the latter 4 weeks, and the physiological saline gastric lavage dose is 10mL/kg body weight;
group c (high sugar high fat feed+Phellinus linteus polysaccharide group): feeding with high-sugar and high-fat feed for 16 weeks, wherein the mice are subjected to gastric administration of Phellinus linteus polysaccharide twice a day, wherein the gastric administration dosage of Phellinus linteus polysaccharide is 50mg/kg body weight, and the administration mode is that Phellinus linteus polysaccharide is dissolved in physiological saline, and then gastric administration is performed, wherein the concentration of Phellinus linteus polysaccharide dissolved in physiological saline is 5 mg/mL.
Wherein, the male C57BL/6 mice, the standard feed and the high-sugar high-fat feed are provided by the experimental animal center of the Hubei province disease control center, and the formula of the high-sugar high-fat feed is as follows (according to the energy ratio): 39.5% lard, 5.5% soybean oil, and 20% sucrose. Phellinus linteus polysaccharide is provided by professor Dr. Jennifer Wan, university of hong Kong, and is extracted by the following method: dissolving Phellinus linteus fruiting body extract in a mixed solution of ultrapure water and ethanol (volume ratio of ultrapure water to ethanol is 1:2) at-20deg.C, centrifuging for 1 hr by 3000g to obtain precipitate, namely Phellinus linteus polysaccharide, lyophilizing, and storing at-80deg.C. When the Phellinus linteus polysaccharide is administered to mice by gastric lavage, the Phellinus linteus polysaccharide is dissolved in physiological saline with a concentration of 5mg/mL, and then administered by gastric lavage.
The three groups of experimental mice were tested for their composition of intestinal flora, mRNA expression levels of intestinal close-coupled related proteins ocln and tjpl, and serum endotoxin LPS levels, respectively, at 16 weeks of feeding, and the test results are shown in fig. 1-4, below, where P represents the P value P1 (group c to group a ratio), where P1 < 0.05, P1 < 0.01, and P1 < 0.001, respectively; # represents the P value P2 (group c to group b ratio), where # and # are P2 < 0.05 and P2 < 0.01, respectively.
(1) Intestinal flora composition test
Intestinal flora composition can be tested by Denaturing Gradient Gel Electrophoresis (DGGE), a common method for identifying colony composition by sequence analysis of the bands or hybridization with specific probes, generally comprising three steps: nucleic acid extraction, PCR amplification of a 16SrRNA sequence and DGGE fingerprint analysis, wherein each band represents a dominant microbial flora of a microorganism through the fingerprint obtained after DGGE, and the variety of the dominant microbial flora can be obtained through sequencing and sequence comparison.
The three groups of experimental mice are respectively tested for intestinal flora structure when being fed for 16 weeks by a DGGE method, and the specific test method is as follows: the total DNA of intestinal flora in the fecal-like content of the intestinal colon segment of the mouse is extracted, and the 16SrDNA sequence is subjected to Polymerase Chain Reaction (PCR) amplification, and then the intestinal flora composition and the relative abundance change are identified by a denaturing gradient gel electrophoresis (PCR-DGGE) technology. The test results are shown in fig. 1, and as shown in fig. 1, the intestinal flora composition and the relative abundance of mice fed with standard feed, mice fed with high-sugar and high-fat feed and mice interfered with Phellinus linteus polysaccharide are obviously different, which indicates that the intestinal flora structure of the mice fed with high-sugar and high-fat feed is disturbed, and the intestinal flora composition of the mice is restored to be close to that of the mice fed with standard feed after the dry Phellinus linteus polysaccharide is used, thus proving that Phellinus linteus polysaccharide has the effect of regulating the intestinal flora structure.
Further sequencing of the differential bands identified by PCR-DGGE revealed that the relative abundance of the deleterious gram negative bacteria Porphyromonas (Porphyromonas) affecting the intestinal barrier was greatly different. Excessive porphyromonas can destroy the normal flora balance of the intestinal tract and lead to the destruction of the barrier of the intestinal wall, so that toxins produced by germs in the intestinal tract are more likely to invade the body, and inflammation of the intestinal tract and the liver and liver injury are induced. As shown in figure 1, the high-sugar high-fat feed-fed mouse fecal sample contains relatively high-abundance porphyromonas, and after the Phellinus polysaccharide is dried, the relative abundance of the porphyromonas is obviously reduced, which indicates that the Phellinus polysaccharide has the effect of inhibiting overgrowth of intestinal harmful bacteria caused by high-sugar high-fat diet, such as the porphyromonas, and the like, so as to regulate the intestinal flora to restore to normal, and can be used for treating or preventing metabolic diseases, such as obesity, non-alcoholic fatty liver, diabetes, hyperlipidemia, cardiovascular and cerebrovascular diseases, and the like, caused by the imbalance of the intestinal flora.
(2) mRNA expression level test of intestinal tract tight junction related proteins ocln and tjpl
FIGS. 2 and 3 show the results of the test of the mRNA expression levels of the intestinal wall-close junction associated proteins ocln and tjpl in the above three groups of experimental mice, wherein the relative expression levels of the intestinal wall-close junction associated proteins ocln in the mice of groups a, b and c were 1.001, 0.7384 and 0.9892, respectively, and the relative expression levels of the intestinal wall-close junction associated proteins tjpl were 1.000, 0.7317 and 0.9064, respectively. From fig. 2 and fig. 3, it can be seen that mRNA expression levels of the closely-linked related proteins ocln and tjpl in the intestinal wall of mice are significantly reduced in the intestinal tissues of mice fed with the high-sugar and high-fat feed, and recovered in the Phellinus linteus polysaccharide intervention group, which indicates that the intestinal harmful bacteria caused by the high-sugar and high-fat diet are increased, resulting in reduced closure and increased permeability of the intestinal wall of the intestinal tract of mice, so that intestinal flora is more likely to invade the body, immune response and inflammatory response are induced, and Phellinus linteus polysaccharide has the effect of recovering the intestinal immune barrier.
(3) Serum endotoxin LPS level assay
Endotoxin is a general term for toxic substances present in bacterial cells of gram-negative bacteria such as typhoid bacillus, tubercle bacillus, shigella dysenteriae and the like, and its main component is lipopolysaccharide (LipopolySaccharide, LPS) in the cell wall of gram-negative bacteria, which is toxic to the host, and is released only when the bacteria die and dissolve or the bacterial cells are destroyed by artificial methods, and is therefore called endotoxin. After the endotoxin invades the host body, the endotoxin can cause the activation of immune cells and the release of a large amount of inflammatory factors, so that symptoms such as fever, leucocyte number change and the like appear, and if the endotoxin content in blood is greatly increased, the symptoms such as endotoxemia, heart failure, renal hypofunction, liver injury, shock and the like can also be caused, and the symptoms such as multi-organ failure and even death are caused in the worst case. Even low levels of endotoxin, such as long-term persistence, can cause chronic inflammation, which in turn can induce metabolic diseases, autoimmune enteritis, fatty liver and steatohepatitis, neurological disorders such as depression, etc. The mechanism of initiation of endotoxemia is: increased abundance of gram-negative bacteria in the gut, increased endotoxin production and impaired intestinal mucosal immune barrier function, translocation of endotoxin into the blood circulation, etc.
Endotoxin determination can be performed by using a detection kit of enzyme-linked immunosorbent assay (enzyme linked immunosorbent assay, ELISA), and the detection results are shown in FIG. 4, wherein the serum endotoxin LPS levels of mice in group a, group b and group c are 0.1022EU/mL, 0.4091EU/mL and 0.2297EU/mL, respectively. As can be seen from fig. 4, the serum endotoxin LPS level of mice is significantly increased in mice fed with high-sugar and high-fat feed, and the normal level is restored after the Phellinus linteus polysaccharide is dried, which indicates that Phellinus linteus polysaccharide intervention can reduce the possibility of endotoxin translocation into the blood circulation by restoring the tight junction of the intestinal wall and enhancing the intestinal wall closure, thereby alleviating the problems of intestinal flora disorder, immunity and inflammation caused by the increase of endotoxin, and damage of intestinal tract, liver and nervous system caused by inflammation, including crohn's disease (an inflammatory disease of intestinal tract, the etiology of which has a certain relationship with humoral immunity and cellular immunity), autoimmune diseases such as enteritis, and nervous system diseases such as depression.
As described above, it is revealed that Phellinus linteus polysaccharide has effects of inhibiting overgrowth of intestinal harmful bacteria such as Porphyromonas caused by high-sugar and high-fat diet, improving intestinal wall closure decrease and endotoxin invasion into host increase caused by intestinal harmful bacteria such as Porphyromonas, reducing possibility of endotoxin entering blood circulation through intestinal wall, and finally achieving effects of regulating intestinal flora to restore normal, relieving endotoxin level increase and chronic inflammation caused by intestinal flora disorder, thereby being useful for treating or preventing intestinal flora disorder, and also treating or preventing metabolic diseases such as obesity, non-alcoholic fatty liver, diabetes, hyperlipidemia, cardiovascular and cerebrovascular diseases caused by intestinal flora structural change, and inflammation related diseases such as enteritis, steatohepatitis, autoimmune diseases (Crohn's disease), nervous system diseases (depression) caused by intestinal flora disorder and intestinal wall permeability increase. The Phellinus linteus polysaccharide can be taken as active ingredient in medicine or health food in the form of tablet, oral liquid, capsule or injection, etc., and can be taken orally or by injection with daily intake of 50mg/kg body weight.
The foregoing description is only of the preferred embodiments of the present invention, and is not intended to limit the scope of the invention, but rather is intended to cover any equivalents of the structures or equivalent processes disclosed herein or in the alternative, which may be employed directly or indirectly in other related arts.
Claims (2)
1. The application of Phellinus linteus polysaccharide in preparing medicine and health food for inhibiting growth of porphyromonas enterica in intestinal flora is provided.
2. Use according to claim 1, said medicament or health food being for intestinal dysbacteriosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710974040.XA CN107496438B (en) | 2017-10-13 | 2017-10-13 | Application of Phellinus linteus polysaccharide in preparing medicine and health food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710974040.XA CN107496438B (en) | 2017-10-13 | 2017-10-13 | Application of Phellinus linteus polysaccharide in preparing medicine and health food |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107496438A CN107496438A (en) | 2017-12-22 |
| CN107496438B true CN107496438B (en) | 2023-10-24 |
Family
ID=60701527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710974040.XA Active CN107496438B (en) | 2017-10-13 | 2017-10-13 | Application of Phellinus linteus polysaccharide in preparing medicine and health food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496438B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111019008B (en) * | 2019-12-13 | 2022-04-05 | 浙江省农业科学院 | Anti-inflammatory activity phellinus igniarius polysaccharide SHP and preparation method thereof |
| CN113817078B (en) * | 2021-10-20 | 2022-11-18 | 吉林农业大学 | Poplar yellow fungus polysaccharide with anti-colorectal cancer effect based on immune regulation and control and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720785A (en) * | 2004-08-12 | 2006-01-18 | 陈全勇 | An artificial high-yield cultivation method of male agaric and application of fruit body thereof |
| CN103405639A (en) * | 2013-08-05 | 2013-11-27 | 福建农林大学 | Phellinus igniarius polyose and traditional Chinese medicine compound blood-glucose lowering oral liquid and preparation method thereof |
-
2017
- 2017-10-13 CN CN201710974040.XA patent/CN107496438B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720785A (en) * | 2004-08-12 | 2006-01-18 | 陈全勇 | An artificial high-yield cultivation method of male agaric and application of fruit body thereof |
| CN103405639A (en) * | 2013-08-05 | 2013-11-27 | 福建农林大学 | Phellinus igniarius polyose and traditional Chinese medicine compound blood-glucose lowering oral liquid and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| γ-Ionylidene-type sesquiterpenoids possessing antimicrobial activity against Porphyromonas gingivalis from Phellinus linteus and their absolute structure determination;Tatsuya Shirahata等;《The Journal of Antibiotics》;第70卷;第695-698页 * |
| 桑黄多糖的研究进展;朗明紫等;《桑蚕通报》;20170531;第48卷(第2期);第14-18页 * |
| 桑黄提取物对C3H10t1/2细胞增殖与成脂分化的影响;蓝巧帅等;《毒理学杂志》;20170630;第31卷(第3期);第215-218页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107496438A (en) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Phellinus linteus polysaccharide extract improves insulin resistance by regulating gut microbiota composition | |
| EP3165227B1 (en) | Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria | |
| US11666607B2 (en) | Nanovesicles derived from Faecalibacterium prausnitzii and uses thereof | |
| CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
| KR20190039502A (en) | New Uses and Methods | |
| CN107496438B (en) | Application of Phellinus linteus polysaccharide in preparing medicine and health food | |
| Lu et al. | Bifidobacterium animalis F1-7 in combination with konjac glucomannan improves constipation in mice via humoral transport | |
| CN114917208A (en) | Application of white spirit in preparing medicine for improving intestinal barrier function and intestinal flora | |
| Han et al. | Ameliorating the efficacy of galacto-oligosaccharides on ovalumin-induced allergic dermatitis symptoms in Balb/c mice by regulating Th2 immune response and the ecosystem of gut microbiota | |
| CN108186740B (en) | Medicine prepared from corydalis saxicola bunting extract for treating intestinal disorder and pharmaceutical application thereof | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| Wang et al. | Effects of sheep whey protein combined with Fu brick tea polysaccharides and stachyose on immune function and intestinal metabolites of cyclophosphamide‐treated mice | |
| CN115252638B (en) | Preparation method and application of quinoa dietary fiber for improving intestinal inflammation | |
| US11554144B2 (en) | Nanovesicles derived from enhydrobacter bacteria, and use thereof | |
| KR102122894B1 (en) | Nanovesicles derived from Exiguobacterium bacteria and Use thereof | |
| RU2673555C2 (en) | Method for application yagel detox dietary supplement as means for treatment of multiple drug resistance tuberculosis | |
| JP7054956B2 (en) | Nanovesicles derived from Rhizobium bacteria and their uses | |
| CN114028414B (en) | Application of mugwort leaf polysaccharide in preparation of medicines for preventing and treating inflammatory bowel disease | |
| KR102118993B1 (en) | Nanovesicles derived from Prevotella bacteria and Use thereof | |
| Fukasawa et al. | Evaluation of Fermented Product, PS-B1, Obtained from Soybean Milk Using Lactic Acid Bacteria in a Stelic Animal Model (STAM?) of Nonalcoholic Steatohepatitis-A Preliminary Study. | |
| WO2023099579A1 (en) | Prevention or treatment of hepatic steatosis | |
| RU2321393C1 (en) | Method for treating calves at inspecific catarrhal bronchopneumonia | |
| CN105997983B (en) | Application of the 5 hydroxymethyl furfural in preparing Anti-helicobacter pylori drugs | |
| Guo et al. | The alleviated symptoms in ovalbumin‐allergic mice treated with selenium‐enriched tea polysaccharide by modulation of intestinal flora and gut metabolites | |
| Lee et al. | Anti-Inflammatory Effects of Artemisia argyi H. Fermented by Lactobacillus plantarum in the LPS-Induced RAW 264.7 Cells and DSS-Induced Colitis Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |